Navigation Links
Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
Date:10/29/2009

nfacine or any of its inactive ingredients or by patients taking other products containing guanfacine.

Hypotension, bradycardia, and syncope were observed in clinical trials. Use INTUNIV with caution in treating patients who have experienced hypotension, bradycardia, heart block, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy. Patients should be advised to avoid becoming dehydrated or overheated.

Sedation and somnolence were commonly observed in clinical trials. The potential for additive sedative effects with CNS depressant drugs should be considered. Patients should be cautioned against operating heavy equipment or driving until they know how they respond to INTUNIV. Avoid use with alcohol.

Common adverse reactions in patients taking INTUNIV that may be dose related over the range of 1 to 4 mg/day include somnolence, sedation, abdominal pain, dizziness, hypotension/decreased blood pressure, dry mouth, and constipation.

VYVANSE IMPORTANT SAFETY INFORMATION

Vyvanse is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and one controlled trial in adults.

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.

Vyvanse should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
2. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
3. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
4. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
5. New Hampshire Rx Card Launching Statewide
6. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
7. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
8. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... International Isotopes Inc. (OTCQB: INIS) (the "Company") ... 31, 2014.  The Company reports a 10% increase in ... cash flow for the year ended December 31, 2014. ... approximately $7.5 million compared to approximately $6.8 million in ... the exception of the radiological services segment, our three ...
(Date:4/1/2015)... , April 1, 2015 ... Report on Global Azithromycin Industry and 2015 ... Industry reports added to Pharmaceutical category in ... the report introduces Azithromycin basic information, including ... overview, policy analysis, and news analysis, etc. ...
(Date:4/1/2015)... 1, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... enrolled in its Glucose Clamp Study. The study will ... Center at San Antonio and ... of Professor Ralph DeFronzo . The ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3
... Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director ... in the field of vascular surgery, is once again leading ... country to use the new VenaCure® 1470nm laser to treat ... compared with other lasers resulting in effective vein closure. ...
... Enzymatics , Inc. announced today that the company, ... forecasting triple the revenue in 2011 over 2010 figures. ... facility in Beverly, Massachusetts.  The move is one of ... firm that supplies biological reagents as well as bio-processing ...
Cached Medicine Technology:Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser 2Enzymatics Reports Latest Growth Figures; Confirms Massachusetts' Emerging Role as Leading Bio-manufacturing Center 2
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross and ... (Blue Cross) today announced audited financial results for 2014. ... of $61.5 million, reflecting positive investment portfolio performance that ... operating loss of $8.2 million on full-year revenues of ... of one percent (0.1%). , Blue Cross reported ...
(Date:4/1/2015)... SCI Solutions , the health ... announced that CEO Joel French will be a featured ... Exhibition in Chicago, April 12-16, 2015. French will ... Care Coordination Strategies ” with Northeast Georgia Health System ... More than 38,000 healthcare industry professionals are expected at ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will ... discuss the benefits of the LANAP® treatment over traditional ... disease. People who live in Howard County, and surrounding ... now visit Dr. Stewart, a Maryland dentist, for a ... LANAP® protocol, which is a laser gum surgery procedure, ...
(Date:4/1/2015)... Dr Roz Kamani, a Vancouver medical aesthetic ... her patients an opportunity to learn more about the ... Days”, which is an exclusive VIP event conducted three ... Care Clinic. It is attended by Dr Roz Kamani’s ... products and services that are on offer. , ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might want ... post discusses Teen Violence Related to Substance Abuse. As ... Awareness Month, the substance abuse treatment center has issued ... identify if there may be problems with their kids ... alcohol. , “People learn how to establish healthy relationships ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... traditional Chinese medicine (TCM) is one of the ... of gastrointestinal microflora are broken, which plays many ... of the host. Therefore, more clinical interests are ... intestinal disease and the consequent treatment, especially in ...
... are top at boozing! In the current edition of ... 106 (19): 323𔃆), Martin Stolle et al. of the ... in Hamburg report that the main change has been ... their article, the authors present motivating short-term interventions to ...
... clinically by a simple method as a preoperative renal ... filtration rate (GFR). Recently, an equation for estimated GFR ... has been accepted as equal to measured GFR in ... studies regarding the reliability of eGFR as a preoperative ...
... that you can personalize.PITTSBURGH, May 22 ... of Computerized Maintenance Management Systems (CMMS) for the healthcare ... personalize.This new product offering is a CMMS application that ... business problems. Users can create their own screen layouts ...
... Third Annual Gout Awareness Day (May 22) NEW YORK, ... announced today that new survey results reveal alarming gaps in ... form of arthritis that affects three to five million Americans. ... of adults admitted to being "not at all knowledgeable" about ...
... Health Group Inc. ("AIM" or the "Company") (TSXV - ... that its income for the three months ended March ... loss of $32,194 in the same period in 2008. ... from $248,810, on a quarter-over-quarter basis. This is the ...
Cached Medicine News:Health News:An efficient approach to monitor gastrointestinal microflora changes 2Health News:A first choice of renal function tests in hepatectomy patients 2Health News:Four Rivers Software System Launches TMS OnSite Professional 2Health News:The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout 2Health News:The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout 3Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 2Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 3Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: